Oral anabolic androgenic steroid

Stanozolol (Winstrol Oral)

Stanozolol is an anabolic steroid; the US Winstrol label lists hereditary angioedema and gives no half-life.1 FDA withdrew approval of the 2 mg tablets application in 2010; the holder said it was no longer marketed.2

Strong evidenceGet the app

Level after one dose

Stanozolol (Winstrol Oral) after one dose: 50% at ~9 h, 25% at 18 h, 12.5% at 27 h.

Drawn from the half-life in the app's model, ~9 h. The model's figures

Stanozolol is an anabolic steroid that was marketed in the United States as Winstrol tablets, and the US label describes 2 mg tablets for oral administration.1 The label's indication section lists hereditary angioedema, written as prophylactic use to decrease the frequency and severity of attacks.1 The label also states that anabolic steroids have not been shown to enhance athletic ability.1

In its 2010 Federal Register notice, FDA lists Winstrol (stanozolol) tablets, 2 mg, application NDA 12-885, among products whose holders told the agency in writing that they were no longer marketed, with withdrawal of approval effective 20 August 2010.2 The Strong Evidence label shown with this compound is the app's own grade, not a conclusion of the sources: the label itself describes "small scale clinical studies", and several trials below report null results.1

The label describes anabolic steroids as synthetic derivatives of testosterone and states that complete dissociation of anabolic and androgenic effects has not been achieved.1

For hereditary angioedema, the label describes a disorder caused by a deficient or nonfunctional C1 esterase inhibitor (C1 INH), states that stanozolol increased serum levels of C1 INH and C4 in small scale clinical studies, and says the effect "may be related to an increase in protein anabolism".1 In the patients of Sheffer and colleagues, C1 inhibitor and C4 rose above pretherapy levels on maintenance therapy but "remained below the lower limit of normal range".3 Agostoni and colleagues compared 17-alpha-alkylated steroids (danazol and stanozolol) with non-17-alpha-alkylated derivatives, and the second group "proved ineffective".4 In 11 male weight lifters given oral stanozolol 6 mg a day for six weeks, postheparin hepatic triglyceride lipase activity rose by 123%, against a non-significant maximum change of 25% with intramuscular testosterone enanthate 200 mg a week.5

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~9 h
Bioavailability
95%
Typical dose
25–50 mg/day
Route
Oral
Time to peak
~1.5 h

The app's figures for oral stanozolol are a half-life of 9 hours, a bioavailability of 95% and a time to peak of 1.5 hours. The US label text read gives none of the three, as the table shows.1

Table 3.1Half-life and pharmacokinetics5 rows
MeasureApp figureSource figure
Half-life~9 hThe label text gives no half-life figure.1
Bioavailability95%The label text gives no bioavailability figure.1
Time to peak~1.5 hThe label text gives no time to peak.1
RouteOralTablets for oral administration.1
Detection in urineNot in the appExcretion study samples show detection windows of up to 12 days for stanozolol-1'N-glucuronide and up to almost 28 days for 17-epistanozolol-1'N-glucuronide. Dose, route and number of participants are not stated in the record.6

A search of PubMed on 16 November 2026 for stanozolol with "half-life" in the title or summary returned 2 records, and a second for stanozolol with pharmacokinetic or bioavailability terms, excluding horse and equine records, returned 4, one of them in both. Together they were 5 distinct records, a Thoroughbred horse study, a rat excretion study, a PEGylated stanozolol design paper, a cyclosporine study in children with aplastic anemia and a review chapter, and by their titles none is a human study of oral stanozolol's half-life or bioavailability. The urinary metabolite detection windows above come from excretion study samples, in a study funded by Seibersdorf Labor GmbH, University of Tromsø and the Partnership for Clean Competition, and are timings of detection, not a plasma half-life.6 The chart below is an illustrative model built from the app's half-life of 9 hours and time to peak of 1.5 hours, not a measured curve; its intervals are the label's maintenance schedules of 2 mg a day and 2 mg on alternate days and the twice-daily schedule of the venous ulcer trial.1,7

Level over 4 days

Interval between doses

Level, as a share of the peak after one 2 mg dose

As studied: every 12 hours7, every 24 hours1, every 48 hours1.

An illustration from a pharmacokinetic model using a half-life of 9 hours. It is not a measured level or a suggested dose.

4

Human studies

The studies below enrolled 11 to 62 people and most are decades old, and three give stanozolol with another drug.

Table 4.1Human studies10 rows
Study and yearDesignPeopleDose and lengthMain result
Sheffer and colleagues, 19813Dose-response assessment over 2 years; no placebo group described.27 patients with hereditary angioedema.Minimal effective dose 0.5 to 2 mg daily; 4 mg a day also tested.Attacks 1 per 14.6, 1 per 7.2 and 1 per 8.2 weeks at 2, 1 and 0.5 mg daily; menstrual abnormalities and virilization in 4 women, raised creatine phosphokinase in 5 men.3
Chesnut and colleagues, 19838Double-blind, 29 months.46 postmenopausal women with osteoporosis (23 treated, 23 control).Dose not stated in the record.Total body calcium +4.4% in treated women (P under 0.01), unchanged in controls; between-group difference P under 0.03; regional bone mass and bone biopsy showed no significant differences; 76% had SGOT elevations or other side effects.8
Thompson and colleagues, 19895Crossover against testosterone enanthate 200 mg a week intramuscular (supraphysiological).11 male weight lifters.Oral 6 mg a day for six weeks.HDL cholesterol down 33%, HDL2 down 71%, apolipoprotein A-I down 40%, LDL cholesterol up 29%; testosterone enanthate: HDL down 9%, apolipoprotein A-I down 8%, LDL cholesterol down 16%.5
Carson and colleagues, 20157Described in the record as double-blind and placebo-controlled; the comparison arm is leg compression alone.44 patients with lipodermatosclerosis and venous ulcers (21 active, 23 placebo).2 mg twice daily for up to 6 months.HDL fell significantly in 91% on stanozolol; AST and ALT significantly elevated in 29% and 33% of patients (record's wording: "treated with stanozolol or placebo, respectively"), back to baseline after stopping; authors call the rise asymptomatic and temporary.7
McMullin and colleagues, 19919Randomised, double-blind, placebo-controlled; compression stockings for all.60 patients with lipodermatosclerosis.5 mg twice daily for 6 months.Area down 28% (95% CI 5.3 to 46) with stanozolol and 14% (95% CI -2.6 to 31) with placebo; oxygen tension unchanged; side effects more common with stanozolol (P under 0.02).9
Jayson and colleagues, 199110Double-blind crossover.Raynaud's: 19 entered, 11 completed. Systemic sclerosis: 24 entered, 17 completed.Not stated in the record.Raynaud's: non-significant improvement in blood flow; authors: no indication for stanozolol in primary Raynaud's. Systemic sclerosis: marked objective but not subjective improvement in the microcirculation, non-significant improvement in dermal sclerosis; adverse events common in both periods, withdrawals mainly during stanozolol treatment and principally due to anabolic problems.10
Parsad and colleagues, 200111Randomised, double-blind, placebo-controlled; cetirizine in both arms.58 enrolled with refractory chronic urticaria; 26 and 24 evaluable.2 mg twice daily with cetirizine 10 mg daily, 12 weeks.Marked to complete resolution in 17 of 26 with stanozolol and 7 of 24 with placebo (P under 0.01).11
Blamey and colleagues, 198412Randomised, double-blind, placebo-controlled.60 patients having elective abdominal surgery.Intramuscular; regimen not itemised in the record.Deep vein thrombosis on scanning in 11 of 31 on placebo (35%) and 12 of 29 on stanozolol (41%).12
Xiong and colleagues, 201513Prospective controlled study; the control girls had no treatment.44 girls with Turner syndrome treated, 22 untreated controls.Growth hormone 47.6 to 52.4 microgram/kg/day with stanozolol 20 to 35 microgram/kg/day.Final adult height 151.42 against 137.75 cm (P under 0.001); the comparison is the combination against no treatment, and the authors add "with proper delay of oestrogen-induced development".13
Liu and colleagues, 202114Stanozolol with decitabine against decitabine alone (21 vs 41); assignment to groups not described.62 patients with high-risk myelodysplastic syndrome who reached at least a partial remission after 4 decitabine cycles.Maintenance after 4 decitabine cycles; stanozolol dose not stated.Progression-free survival 15.0 against 9.0 months (HR 0.35, 95% CI 0.19 to 0.63); overall survival 21.0 against 15.0 months, not significantly prolonged (HR 0.73, p = 0.33); the record lists no stanozolol-specific adverse events.14

Deeper analysis: hereditary angioedema (Sheffer and colleagues, 1981 and 1987; Sloane and colleagues, 2007)

Sheffer, Fearon and Austen, Journal of Allergy and Clinical Immunology, 1981, gave stanozolol to 12 men and 15 women with biochemically proven hereditary angioedema over 2 years, and all 27 reached a minimal effective dose of 0.5 to 2 mg daily.3 The authors reported that 4 mg a day "caused greater immunochemical responses" but was "unnecessary for control of clinical disease" and "unjustified for chronic therapy because of more frequent side effects".3 The record lists grants from two NIH institutes, describes no placebo group and carries no conflict statement.3 The 1987 report from the Department of Medicine, Harvard Medical School, covered 37 patients, 18 of whom had adverse reactions while the minimal effective dose was attained, and concluded that stanozolol "appears to be a safe and effective agent for management of hereditary angioedema when patients are continually monitored to define the minimal effective dose or the feasibility of stopping the drug"; by 1986, 3 were on daily maintenance, 18 on alternate-day maintenance and 16 on none.15 Sloane, Lee and Sheffer, Journal of Allergy and Clinical Immunology, 2007, noted that "the side-effect frequencies in patients receiving long-term treatment are relatively less well characterized", and their questionnaire study of patients who continued stanozolol therapy since 1987 found treatment-related symptoms in 10 of 21 that subsided with a lower dose; hirsutism, weight gain, menstrual irregularities or postmenopausal bleeding, acne and mood changes; reduced HDL in 5 patients and elevated triglycerides in 2; no persistent liver enzyme abnormalities; and 3 ultrasound abnormalities among 8 patients deemed unrelated to therapy.16

Deeper analysis: lipoproteins (Thompson and colleagues, 1989)

Thompson and colleagues at the Miriam Hospital, Providence, JAMA, 1989, gave 11 male weight lifters oral stanozolol 6 mg a day or intramuscular testosterone enanthate 200 mg a week for six weeks in a crossover design.5 Weight gain was similar and testosterone was more effective in suppressing gonadotropic hormones.5 The authors concluded that the lipoprotein effects of oral 17-alpha-alkylated steroids "are different from those of parenteral testosterone"; the record lists grants from two NIH institutes and no conflict statement.5 Taggart and colleagues, Metabolism, 1982, followed 10 normolipidemic postmenopausal women with osteoporosis for 6 weeks and reported HDL cholesterol down 53% and LDL cholesterol up 21%, with all changes reversed by 5 weeks after stopping, and wrote that the changes "suggest caution in the long term prescription of stanozolol, particularly in those without overriding clinical indications for its use".17

Deeper analysis: postmenopausal osteoporosis (Chesnut and colleagues, 1983)

Chesnut, Ivey, Gruber and colleagues, Metabolism, 1983, ran a 29-month double-blind study of 23 treated and 23 control postmenopausal women with osteoporosis, with grant support from the National Center for Research Resources.8 The between-group difference in total body calcium was significant (P under 0.03), regional bone mass and bone biopsy showed no significant differences, and no new spinal compression fractures were noted in the treated group against three in controls.8 Seventy-six percent of treated women developed SGOT elevations or other side effects, "at no time" severe enough to end medication; the record states no dose and no conflict statement.8

Deeper analysis: lipodermatosclerosis and venous ulcers (McMullin and colleagues, 1991; Carson and colleagues, 2015)

McMullin, Watkin, Coleridge Smith and Scurr, Middlesex Hospital, London, Australian and New Zealand Journal of Surgery, 1991, randomised 60 patients to stanozolol 5 mg or placebo twice daily for 6 months, all in compression stockings.9 The record gives no between-group test for the two area reductions, and the authors wrote that "no evidence of any effect on a possible oxygen diffusion block was indicated".9 Carson, Hong, Otero-Vinas, Arsenault and Falanga, Boston University School of Medicine, International Journal of Lower Extremity Wounds, 2015, studied liver enzymes and lipids in 44 patients, 21 on oral stanozolol 2 mg twice daily for up to 6 months and 23 on leg compression alone.7 The record states that "AST/SGOT and ALT/SGPT became significantly elevated in 29% (P = .0415 at 2 months) and 33% (P = .0182 at 1 month) of patients treated with stanozolol or placebo, respectively", with return to baseline after treatment, and that 91% of patients on stanozolol had a significant HDL decrease.7 The record's wording does not make clear which percentage belongs to which arm, and it gives no per-arm counts.7 Neither record lists a funder or a conflict statement.9,7

Deeper analysis: high-risk myelodysplastic syndrome (Liu and colleagues, 2021)

Liu and colleagues, Tianjin Medical University General Hospital and partner centres, International Journal of Hematology, 2021, selected patients with newly diagnosed high-risk myelodysplastic syndrome who reached at least a partial remission after 4 cycles of decitabine, and of 62 patients 21 had stanozolol with decitabine for maintenance and 41 decitabine alone.14 Severe neutropenia was less frequent with stanozolol (76.2% against 95.1%, p = 0.039), the record does not say how patients were assigned to the groups, and its funding is from the National Natural Science Foundation of China and Tianjin, Beijing and Chinese Academy of Medical Sciences programmes, and the record carries no conflict or limitations statement.14

Jayson's and Xiong's records are both typed as non-US government research support with no grant named; Parsad's and Blamey's list no funder; none carries a conflict statement.10,11,12,13

5

Doses reported in studies and on the label

The app's typical dose range is 25 to 50 mg a day. Of the oral doses stated in the label and the trials, the highest is 10 mg a day (5 mg twice daily) and the lowest 0.5 mg a day, and none of the label or trial texts read reports a dose of 25 to 50 mg a day.1,9,3 The two records read that state a 50 mg dose describe injections: an intramuscular dose 24 hours before surgery in the Blamey group's earlier work, and a 19-year-old man who injected it to improve muscle mass.12,18 The label says dosage is individualized to clinical response, the lowest possible effective dose is called for, and long-term prophylaxis is generally not recommended in children.1

Table 5.1Doses reported in studies and on the label3 rows
SourceDoseFrequencyLength
US label, hereditary angioedema, starting12 mg1Three times a day1Until a favourable initial response, per the label1
US label, hereditary angioedema, maintenance12 mg a day, or 2 mg on alternate days1Daily or alternate days1Not stated; the label reaches this dose by lowering at intervals of one to three months1
Sheffer and colleagues, 198130.5 to 2 mg minimal effective; 4 mg also tested3Daily32 years3

The label's warnings, written for androgenic anabolic steroid therapy as a class, report peliosis hepatis, "a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts", which they say are often not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops.1 The peliosis text adds that withdrawal of the drug usually results in complete disappearance of lesions.1 They also report liver cell tumors, most often benign and androgen-dependent with fatal malignant tumors reported and withdrawal of the drug often resulting in regression or cessation of progression, and blood lipid changes that include decreased high-density lipoprotein and sometimes increased low-density lipoprotein and "may be very marked".1 The adverse reactions section includes cholestatic jaundice with, rarely, hepatic necrosis and death; in postpubertal men, inhibition of testicular function, testicular atrophy and oligospermia; in women, clitoral enlargement, menstrual irregularities and deepening of the voice; and premature closure of epiphyses in children.1 The precautions add that some virilizing changes in women are irreversible even after prompt discontinuance of therapy.1

Nunes and colleagues, Journal of Clinical and Experimental Hepatology, 2025, prospectively evaluated 18 people in the Latin American DILI Registry from 2013 to 2023, all young men aged 19 to 48 using stanozolol for aesthetic purposes, with a mean latency to symptom onset of 55 days, elevated total bilirubin in all and concurrent use of other substances in ten.19 They describe "marked elevation of bilirubin, mild rise in transaminases, and near-normal GGT".19 Stepien and colleagues, Clinical and Experimental Hepatology, 2015, report a 19-year-old man who injected stanozolol 50 mg intramuscularly every other day for 2 months, was admitted with a total bilirubin of 44.34 mg/dl that rose to 56.64 mg/dl with an INR of 1.7 on conservative treatment, was then given low-dose hydrocortisone with bilirubin 14.61 mg/dl after 2 weeks, and had hepatic enzymes back to normal values 5 months after stopping; the biopsy showed toxic hepatitis of minor grade with periportal fibrosis and intrahepatic cholestasis.18 Qin and colleagues, Frontiers in Medicine, 2025, report a 15-year-old with a 6-year history of aplastic anemia treated with long-term oral stanozolol who had a hepatocellular adenoma confirmed and, after transcatheter hepatic artery embolization and a switch to romiplostim, a "significant reduction in lesion size" on a scan 4 months after the drug was stopped.20 Lehmann and colleagues, Forensic Science International, 2019, describe a death with stanozolol, metandienone and clenbuterol in blood (with trenbolone below the limit of quantification) and several other substances in urine; the authors attribute the death to anatomical and substance-induced risk factors together, with long-term steroid use among them, so the case does not isolate stanozolol.21 Hartgens and Kuipers, Sports Medicine, 2004, wrote of androgenic-anabolic steroids as a class that "in studies of athletes, AAS were not found to damage the liver", and that the scientific data "may underestimate the actual untoward effects" because the doses in studies do not approximate those of illicit steroid users.22

7

Bloodwork and markers

Sources in this part

  1. 1Winstrol, 2021

The app lists liver enzymes, lipids and hematocrit as markers for stanozolol. The label lists periodic liver function tests because of the hepatotoxicity associated with 17-alpha-alkylated androgens, periodic serum lipids and HDL cholesterol, and periodic hemoglobin and hematocrit checks for polycythemia in patients receiving high doses of anabolic steroids.1 The label states that anabolic steroids may cause suppression of clotting factors II, V, VII and X and an increase in prothrombin time.1

The label states that Winstrol is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and has been assigned to Schedule III.1 The current text of 21 CFR 1308.13, Schedule III, lists stanozolol among the anabolic steroids in paragraph (f).23 In the Federal Register of 21 July 2010, FDA withdrew approval of NDA 12-885, Winstrol (stanozolol) tablets, 2 mg, listed under Lundbeck, in a notice covering applications whose holders had told the agency in writing that the products were no longer marketed, effective 20 August 2010.2 The notice states that withdrawal under that process "is without prejudice to refiling".2 The World Anti-Doping Agency's 2026 Prohibited List, in force 1 January 2026, places stanozolol in S1.1, anabolic androgenic steroids when administered exogenously, in the class S1 anabolic agents, prohibited at all times, in and out of competition, and non-Specified.24 Goschl and colleagues, Drug Testing and Analysis, 2021, write that stanozolol "stays one of the most detected substances in professional sports".6

9

Storage and handling

Sources in this part

  1. 1Winstrol, 2021

The label describes Winstrol tablets as pink, round tablets scored on one side, supplied in bottles of 100, with the statement "Store at controlled room temperature 15° to 30° C (59° to 86° F)".1

10

What is not known

Sources in this part

  1. 16Sloane et al., 2007

No label or trial text read reports an oral stanozolol dose of 25 to 50 mg a day, the app's typical range. The long-term follow-up read covers 21 patients with hereditary angioedema treated for 20 to 40 years.16 Regulatory status outside the United States is not covered in the sources used.

What is the half-life of Winstrol (stanozolol)?

The app's figure for the half-life of oral stanozolol is about 9 hours. The US Winstrol label text gives no half-life figure.1 Urine detection windows in an excretion study reached up to 12 days and up to almost 28 days for two metabolites, and these are timings of detection, not a half-life.6

Is Winstrol approved by FDA?

FDA withdrew approval of the Winstrol (stanozolol) 2 mg tablets application, NDA 12-885, effective 20 August 2010.2 The notice covered applications whose holders had told FDA in writing that the products were no longer marketed.2 The notice lists one stanozolol application, and RxList's summary page for the drug says generic versions may still be available.1,2 The label's indication was prophylaxis of hereditary angioedema attacks.1

Is Winstrol banned by WADA?

Yes, stanozolol is on the World Anti-Doping Agency's 2026 Prohibited List in S1.1, anabolic androgenic steroids when administered exogenously.24 The class is prohibited at all times, in and out of competition.24

Is Winstrol a controlled substance?

In the United States the Winstrol label states that it is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and assigned to Schedule III.1 21 CFR 1308.13(f) lists stanozolol among the Schedule III anabolic steroids.23

Does Winstrol lower HDL cholesterol?

In 11 male weight lifters given oral stanozolol 6 mg a day for six weeks, HDL cholesterol fell by 33% and LDL cholesterol rose by 29%.5 In 10 postmenopausal women with osteoporosis HDL cholesterol fell by 53% over 6 weeks, and in the venous ulcer trial 91% of those on stanozolol had a significant HDL decrease.17,7 The label states that these changes usually revert to normal on discontinuation of treatment.1

Does Winstrol affect the liver?

The US label reports peliosis hepatis, liver cell tumors and cholestatic jaundice with, rarely, hepatic necrosis and death for androgenic anabolic steroid therapy.1 In the venous ulcer trial of stanozolol 2 mg twice daily, the record states that AST/SGOT and ALT/SGPT "became significantly elevated in 29% (P = .0415 at 2 months) and 33% (P = .0182 at 1 month) of patients treated with stanozolol or placebo, respectively", with return to baseline after treatment.7 In long-term hereditary angioedema patients who had continued therapy since 1987, Sloane and colleagues found no persistent liver enzyme abnormalities, reduced HDL in 5 patients and elevated triglycerides in 2.16 Sheffer and colleagues, 1987, report biochemical evidence of hepatic dysfunction as the most common adverse reaction, with adverse reactions in 18 of 37 patients.15 A registry of 18 young men using stanozolol for aesthetic purposes, ten of whom reported other substances too, found elevated bilirubin in all.19

Does Winstrol lower testosterone?

The label states that anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.1 It lists inhibition of testicular function, testicular atrophy and oligospermia in postpubertal men.1 In six patients on maintenance doses, Sheffer and colleagues reported normal serum testosterone in the four men.3 In the weight lifter crossover trial, testosterone enanthate 200 mg a week was more effective than oral stanozolol 6 mg a day in suppressing gonadotropic hormones.5

13

References

  1. Winstrol (Anabolic steroids): Side Effects, Uses, Dosage, Interactions, Warnings. John P. Cunha, DO, medical editor, RxList; page last updated 4 October 2021; the label text itself is undated. Contains the US prescribing information for Winstrol (stanozolol) tablets, 2 mg (brand no longer available in the US) and RxList's summary of the drug. RxList label text
  2. US Food and Drug Administration. Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications. Federal Register 75 FR 42455, 21 July 2010 (FR Doc 2010-17785). Federal Register notice
  3. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981. PMID 6790595
  4. Agostoni A, et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 1980. PMID 6765962
  5. Thompson PD, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989. PMID 2915439
  6. Goschl L, et al. Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis. Drug Test Anal 2021. PMID 34089570
  7. Carson P, et al. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. Int J Low Extrem Wounds 2015. PMID 25652757
  8. Chesnut CH 3rd, et al. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism 1983. PMID 6341772
  9. McMullin GM, et al. Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency. Aust N Z J Surg 1991. PMID 2018441
  10. Jayson MI, et al. A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1991. PMID 1994867
  11. Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. J Dermatol 2001. PMID 11476107
  12. Blamey SL, et al. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. Thromb Haemost 1984. PMID 6539002
  13. Xiong H, et al. Therapeutic effects of growth hormone combined with low-dose stanozolol on growth velocity and final height of girls with Turner syndrome. Clin Endocrinol (Oxf) 2015. PMID 25824243
  14. Liu Y, et al. Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment. Int J Hematol 2021. PMID 33646527
  15. Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987. PMID 3693762
  16. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007. PMID 17765757
  17. Taggart HM, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 1982. PMID 6813637
  18. Stepien PM, et al. Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature. Clin Exp Hepatol 2015. PMID 28856252
  19. Nunes V, et al. Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at Presentation. J Clin Exp Hepatol 2025. PMID 40040852
  20. Qin YN, et al. Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration. Front Med (Lausanne) 2025. PMID 40909442
  21. Lehmann S, et al. Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). Forensic Sci Int 2019. PMID 31499423
  22. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004. PMID 15248788
  23. US Drug Enforcement Administration. 21 CFR 1308.13 Schedule III. Electronic Code of Federal Regulations, text of the version dated 1 November 2026. eCFR 21 CFR 1308.13
  24. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In force 1 January 2026. WADA Prohibited List 2026